287 filings
Page 6 of 15
8-K
2zsu3sp4
2 Mar 20
FibroGen Reports Fourth Quarter and Full Year 2019 Financial Results
4:06pm
UPLOAD
kdtj4i96rwd
25 Feb 20
Letter from SEC
12:00am
CORRESP
fu1p 4lit17coirf6g
21 Feb 20
Correspondence with SEC
12:00am
UPLOAD
ircivl fjq30
14 Feb 20
Letter from SEC
12:00am
8-K
rg7zee5uo
13 Feb 20
Departure of Directors or Certain Officers
4:05pm
8-K
zrf42uc4pmr th
11 Feb 20
FibroGen Announces U.S. FDA Acceptance of New Drug Application for Roxadustat for the Treatment of Anemia of Chronic Kidney Disease
5:16pm
CORRESP
v76wsx2nafg u0cqs87c
31 Jan 20
Correspondence with SEC
12:00am
8-K
8n3fog
30 Jan 20
Astellas Submits Supplemental New Drug Application for Approval of
4:40pm
8-K
jwrc6x1c2gi5nrq38
13 Jan 20
Regulation FD Disclosure
9:01am
8-K
ckac32lte6off0q982av
6 Jan 20
Fibrogen Names Enrique Conterno As Chief Executive Officer
5:23pm
8-K
a9k9v8ofctknnav
23 Dec 19
Fibrogen Submits New Drug Application to the U.S. Fda for Roxadustat In Patients with Anemia of Chronic Kidney Disease
9:06am
UPLOAD
xob5i0ox
23 Dec 19
Letter from SEC
12:00am
8-K
fzc 02eyjf2
16 Dec 19
Departure of Directors or Certain Officers
12:00am
CORRESP
whlumzbnmd4xvy
13 Dec 19
Correspondence with SEC
12:00am
UPLOAD
12n1i7vn gl8v3xhv
3 Dec 19
Letter from SEC
12:00am
8-K
gccua0lcw01o
2 Dec 19
FibroGen Announces Roxadustat Inclusion in China’s National Reimbursement Drug List
7:10am
8-K
6wb4tf
12 Nov 19
FibroGen Reports Third Quarter 2019 Financial Results
8:16am
8-K
jic be0eg03nxxl
8 Nov 19
Regulation FD Disclosure
2:05pm